| Literature DB >> 30533175 |
Amna Mohamed Al-Thani1, Sven Christian Voss1, Afnan Saleh Al-Menhali1, Andrei Barcaru2, Peter Horvatovich2, Hind Al Jaber1, Zoran Nikolovski3, Aishah Latiff1, Costas Georgakopoulos1, Zeyd Merenkov4, Jordi Segura5, Mohammed Alsayrafi1, Morana Jaganjac1.
Abstract
Autologous blood transfusion (ABT) has been frequently abused in endurance sport and is prohibited since the mid-1980s by the International Olympic Committee. Apart from any significant performance-enhancing effects, the ABT may pose a serious health issue due to aging erythrocyte-derived "red cell storage lesions." The current study investigated the effect of blood storage in citrate phosphate dextrose adenine (CPDA1) on the red blood cell (RBC) membrane proteome. One unit of blood was collected in CPDA1 blood bags from 6 healthy female volunteers. RBC membrane protein samples were prepared on days 0, 14, and 35 of storage. Proteins were digested in gel and peptides separated by nanoliquid chromatography coupled to tandem mass spectrometry resulting in the confident identification of 33 proteins that quantitatively change during storage. Comparative proteomics suggested storage-induced translocation of cytoplasmic proteins to the membrane while redox proteomics analysis identified 14 proteins prone to storage-induced oxidation. The affected proteins are implicated in the RBC energy metabolism and membrane vesiculation and could contribute to the adverse posttransfusion outcomes. Spectrin alpha chain, band 3 protein, glyceraldehyde-3-phosphate dehydrogenase, and ankyrin-1 were the main proteins affected by storage. Although potential biomarkers of stored RBCs were identified, the stability and lifetime of these markers posttransfusion remain unknown. In summary, the study demonstrated the importance of studying storage-induced alterations in the erythrocyte membrane proteome and the need to understand the clearance kinetics of transfused erythrocytes and identified protein markers.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30533175 PMCID: PMC6249999 DOI: 10.1155/2018/6375379
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Age and hematological characteristics of participants.
| Parameter | Unit | Mean ± SD |
|---|---|---|
| Age | Years | 32.17 ± 3.19 |
| WBC | 103/ | 7.77 ± 2.16 |
| LYMPH | % | 37.02 ± 8.37 |
| MONO | % | 8.13 ± 2.03 |
| GRAN | % | 54.85 ± 10.27 |
| RBC | 106/ | 4.95 ± 0.28 |
| Hb | g/dL | 13.30 ± 0.60 |
| Hct | % | 40.93 ± 1.39 |
| PLT | 103/ | 258.00 ± 49.09 |
WBC: white blood cell count; LYMPH: lymphocyte count; MONO: monocyte count; GRAN: granulocyte count; RBC: red blood cell count; Hb: hemoglobin concentration; Hct: hematocrit; PLT: platelet count.
Figure 1The distribution of the data before (a) and after (b) median scale normalization.
Figure 2Heat map of differential proteins determined by the Bayesian test comparing day 0 to day 14 and day 0 to day 35 (FDR = 0.05). Protein ID description with fold change on the day 14 and day 35 is indicated in the Supplemental Table S2.
Oxidative modification of proteins ubiquitously present in samples irrespective of storage. Modifications labeled with Ox or C represent either peptide oxidation or peptide carbonylation, respectively.
| Accession | Description | Sequence | Modification | ||
|---|---|---|---|---|---|
| Day 0 | Day 14 | Day 35 | |||
| A0A0K2BMD8 | Mutant hemoglobin alpha 2 globin chain | VADALTNAVAHVDD | Ox | Ox | |
| P00558 | Phosphoglycerate kinase 1 | AHSS | Ox | ||
| IQLINN | Ox | Ox | |||
| SVVLMSHLGRPDGVP | Ox | ||||
| VNE | Ox | ||||
| P02042 | Hemoglobin subunit delta | EFTPQ | Ox | ||
| P02549 | Spectrin alpha chain, erythrocytic 1 | AD | Ox, C | Ox | Ox |
| EK | Ox | Ox | |||
| FSSDFDELSGW | Ox | Ox, C | Ox | ||
| LTLSHPSDA | Ox, C | ||||
| SDDKSSLDSLEAL | Ox | Ox | |||
| P02730 | Band 3 anion transport protein | GLDLNGGPDD | C | ||
| YTQEIFSF | C | ||||
| PQGPLPNTALLSLVLMAGTFFFAM | Ox | Ox | |||
| RYQSSPAKPDSS | Ox | ||||
| P04075 | Fructose-bisphosphate aldolase A | IGEHTPSALAI | Ox | ||
| P04406 | Glyceraldehyde-3-phosphate dehydrogenase | WGDAGAEYVVESTGVFTT | Ox | ||
| P11166 | Solute carrier family 2, facilitated glucose transporter member 1 | QGGASQSDKT | C | ||
| SFE | Ox | ||||
| P11171 | Protein 4.1 | S | Ox | Ox | |
| P11277 | Spectrin beta chain, erythrocytic | DEEGAIV | Ox | Ox | |
| DGLNE | Ox | Ox | |||
| DLEDET | C | C | |||
| ESQQL | Ox | ||||
| GLDAHLEQIFQEAHG | Ox | Ox | |||
| HQAFVA | C | ||||
| KEELGELFAQVPS | Ox, C | ||||
| L | Ox | Ox | |||
| QL | C | C | Ox, C | ||
| VISDEIPKDEEGAIV | Ox | ||||
| P16157 | Ankyrin-1 | DIEVLEG | Ox | ||
| EGQNAN | Ox | ||||
| GFTPLY | Ox | ||||
| HGV | Ox | Ox | |||
|
| Ox, C | ||||
| SLLQYGGSANAESVQGVT | Ox, C | ||||
| TGASIDAVTESGLTPLHVASF | Ox | Ox | |||
| VETPLH | Ox | ||||
| P27105 | Erythrocyte band 7 integral membrane protein | EEIAH | Ox | ||
| NLSQILSDREEIAHN | Ox | Ox | |||
| P52209-2 | Isoform 2 of 6-phosphogluconate dehydrogenase, decarboxylating | YGPSL | Ox | ||
| P60709 | Actin, cytoplasmic 1 | KDLYANTVLSGGTT | Ox | ||
Figure 3The impact of storage on (a) the number of oxidized peptides and (b) the type of oxidative modification of amino acid (AA) residues.
Figure 4The heat map of semiquantitative assessment of peptide oxidations determined by Bayesian testing comparing day 0 to day 14 and day 0 to day 35 (FDR = 0.05): (a) protein ID description and peptide sequence are indicated in the table below the heat map; (b) PCA scatter plot showing the difference in the groups due to the oxidation.
Figure 5Repartition of molecular functions (a) and biological processes (b) corresponding to erythrocyte membrane proteins altered with the storage process.